National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Anticancer Res. 2009 Nov;29(11):4665-71.
A 46-year-old woman with history of radioiodine-refractory follicular thyroid carcinoma (FTC) presented with locally recurrent, high-risk, invasive disease. She was treated with paclitaxel/carboplatin concomitant chemoradiotherapy (CRT), which was well tolerated, resulting in complete remission and freedom from residual or recurrent FTC for longer than 5 years until her last follow-up at age 52. This case highlights the possibility of combining taxane-based chemotherapy with definitive radiotherapy (as CRT) for the management of locally aggressive recurrences in poorly differentiated thyroid carcinoma, thereby resulting in rapid and persistent disease eradication. Even in the light of recent data on the potential benefit of novel targeted therapy agents in poorly differentiated thyroid carcinoma, this approach in similar clinical settings deserves future investigation.
一位 46 岁的女性，患有放射性碘难治性滤泡甲状腺癌（FTC）病史，出现局部复发性、高危、侵袭性疾病。她接受了紫杉醇/卡铂联合化疗同步放化疗（CRT），耐受性良好，完全缓解，无残留或复发性 FTC 超过 5 年，直至她最后一次随访时 52 岁。这个病例突出了在低分化甲状腺癌中，用基于紫杉醇的化疗联合根治性放疗（如 CRT）治疗局部侵袭性复发的可能性，从而实现快速和持久的疾病消除。即使考虑到最近关于新型靶向治疗药物在低分化甲状腺癌中潜在获益的数据，这种在类似临床情况下的方法值得未来进一步研究。
